NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
25.50
+0.04 (0.16%)
Dec 20, 2024, 4:00 PM EST - Market closed
NAMS Employees
NewAmsterdam Pharma Company had 29 employees as of December 31, 2023. The number of employees increased by 12 or 70.59% compared to the previous year.
Employees
29
Change (1Y)
12
Growth (1Y)
70.59%
Revenue / Employee
$1,158,414
Profits / Employee
-$6,859,172
Market Cap
2.36B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 29 | 12 | 70.59% |
Dec 31, 2022 | 17 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Select Medical Holdings | 54,600 |
Addus HomeCare | 34,846 |
Ardent Health Partners | 23,000 |
Amneal Pharmaceuticals | 7,700 |
Azenta | 3,300 |
Privia Health Group | 1,102 |
Arrowhead Pharmaceuticals | 609 |
Geron | 141 |
NAMS News
- 8 days ago - NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 10 days ago - NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 10 days ago - NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts - Seeking Alpha
- 10 days ago - Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
- 11 days ago - NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 11 days ago - Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - Benzinga
- 11 days ago - NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia - GlobeNewsWire
- 15 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire